急性髓细胞白血病缓解后FA方案巩固治疗的临床疗效

目的探讨急性髓细胞白血病（AML）缓解后FA方案巩固治疗的效果。方法63例常规化疗获完全缓解的AML患者分为实验组和对照组．实验组30例采用FA方案巩固治疗，对照组33例采用阿糖胞苷（Ara—C）巩固治疗，对两组患者进行随访．分析比较两组的生存率。结果实验组中位生存时间为48月，对照组中位生存时间为37月（P〈0．05）。实验组和对照组3年无病生存率（DFS）和无痛生存率分别为63．3％和52．0％（P〈0．05），4年DFS分别为48．8％和41．6％（P〈0．05）；实验组和对照组3年OS（总生存率）分别为73．3％和58．8％（P〈0．05），实验组和对照组4年OS分别为59．5％和48．4％（P〈0．05）。两组患者在骨髓抑制期间血细胞减少的持续时间、发生感染几率方面无显著性差异，支持治疗输注红细胞和血小板量亦无显著性差异。结论FA方案强化巩固治疗AML中位生存时间、3年及4年生存率高于单用阿糖胞苷巩固治疗。

Clinical efficacy of FA regimen for postremission consolidation in acute myeloid leukemia

Objective To investigate efficacy of FA regimen for postremission consolidation in acute myeloid leukemia （AML）. Methods 63 patients with AML who had a complete remission after conventional induction chemotherapy were assigned to study group and control group.30 patients in the study group were consolidated with FA regimen and the 33 patients in the control group were consolidated with cytosine arabinoside （Ara-C）.Follow-up was carried out and DFS and OS of the patients in the two groups were compared. Results The median survival time was 48 and 37 months in the study group and control group , respectively（P〈0.05 ）.The 3-year DFS was 63.3% and 52.0% in the study group and control group, respectively（P〈0.05）. The 4-year DFS was 48.8% and 41.6% in the study group and control group,respectively （P〈0.05）.The 3-year OS was 73.3% and 58.8% in the study group and control group,respectively（P〈0.05）.The 4-year OS was 59.5% and 48.4% in the study group and control group,respectively（P〈0.05 ）.There were no significant differences in the time of duration of cytopenia during myelosuppression period,infection rates, amount of red cell transfusion and platelct transfusion between the two groups. Conclusion The median survival time, 3-year and 4-year survival rates are higher in AML patients consolidated with FA regimen than those in AML patients consolidated with Ara-C.